Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 15/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744243 | 0.91 | GRIK1 (0.71) | GRIK1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL6431737 | 0.89 | GRIK1 (1.00) | GRIK1MEN1KMT2ARAB9AGRIK2 | |
| SCHEMBL5595292 | 0.88 | GRIK1 (0.71) | GRIK1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL23831319 | 0.87 | GRIK1 (0.62) | GRIK1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL23831312 | 0.85 | GRIK1 (0.60) | GRIK1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL23831493 | 0.85 | GRIK1 (0.60) | GRIK1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL26596770 | 0.83 | AKR1C3 (0.58) | GRIK1RAB9AMAPTNPC1 | |
| SCHEMBL27193042 | 0.82 | RAB9A (0.79) | MEN1KMT2ARAB9AMAPTNPC1 | |
| SCHEMBL30851500 | 0.82 | RAB9A (0.79) | MEN1KMT2ARAB9AMAPTNPC1 | |
| SCHEMBL23831273 | 0.81 | MEN1 (0.60) | GRIK1MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | GRIK1 655/4885MEN1 903/4885KMT2A 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.